title: Effect of HLA mismatch on acute graft-versus-host disease.
abstract: HLA matching between donors and recipients is the most important factor associated with acute graft-versus-host disease (GVHD) following allogeneic hematopoietic stem cell transplantation. With improvements in GVHD prophylaxis and supportive care, transplantations from HLA mismatched donors are performed increasingly frequently, drawing greater attention to the effects of HLA mismatch. In related transplantation, HLA 1-antigen mismatch at the HLA-A, HLA-B, and HLA-DR loci is considered acceptable, but the incidence of severe acute GVHD under standard prophylaxis is higher than that for matched related and unrelated transplantation, highlighting the need for a modification of GVHD prophylaxis. Development of new GVHD prophylaxes has now made HLA 2-3-antigen mismatched related transplantation feasible, and has almost overcome the HLA barrier. In unrelated bone marrow or peripheral blood stem cell transplantation, donors matched for HLA-A, HLA-B, HLA-C, and HLA-DRB1 alleles are the most preferable. The impact of allele or antigen mismatch has been evaluated in a number of studies, but the results of these have not been consistent, partly due to differences in race and HLA distribution. The effects of HLA mismatch may differ depending on the year of transplantation and the form of GVHD prophylaxis administered. In cord blood transplantation, successful transplantation can be achieved with up to two HLA mismatches. In children, compared to the use of HLA mismatched units, the use of HLA-matched units is associated with a lower risk of acute GVHD and mortality, while in adults HLA mismatches may have a lower impact on outcome. Thus, the effect of HLA matching should be evaluated separately for different stem cell sources.
authors.affiliation: Division of Hematology, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma-cho, Omiya-ku, Saitama, Saitama, 330-8503, Japan, jkandajp@gmail.com.
authors.forename: Junya
authors.initials: J
authors.lastname: Kanda
mesh_terms: D000208:Acute Disease; D000328:Adult; D000483:Alleles; D064591:Allografts; D016026:Bone Marrow Transplantation; D002648:Child; D006086:Graft vs Host Disease / Q000235:genetics* / Q000276:immunology* / Q000401:mortality / Q000517:prevention & control; D006680:HLA Antigens / Q000235:genetics* / Q000276:immunology*; D018380:Hematopoietic Stem Cell Transplantation; D006650:Histocompatibility Testing; D006801:Humans; D012306:Risk; D015996:Survival Rate
chemical_list: D006680:HLA Antigens
references.citation: N Engl J Med. 1998 Oct 22;339(17):1177-85
references.pmid: 9780337
references.citation: Blood. 2007 Dec 15;110(13):4576-83
references.pmid: 17785583
references.citation: J Clin Oncol. 2007 Feb 20;25(6):690-7
references.pmid: 17228020
references.citation: Blood. 2003 Aug 15;102(4):1541-7
references.pmid: 12714500
references.citation: Haematologica. 2011 Aug;96(8):1213-20
references.pmid: 21546497
references.citation: Blood. 2001 Nov 15;98(10):2922-9
references.pmid: 11698272
references.citation: Blood. 2002 Jun 1;99(11):4200-6
references.pmid: 12010826
references.citation: Blood. 2012 Mar 8;119(10):2409-16
references.pmid: 22042692
references.citation: Hum Immunol. 1990 Oct;29(2):79-91
references.pmid: 2249952
references.citation: Blood. 2006 Apr 15;107(8):3065-73
references.pmid: 16380454
references.citation: Exp Hematol. 2008 Jan;36(1):1-8
references.pmid: 17920757
references.citation: Blood. 2004 Oct 1;104(7):1923-30
references.pmid: 15191952
references.citation: Int J Hematol. 2011 May;93(5):586-593
references.pmid: 21369856
references.citation: N Engl J Med. 1998 Nov 26;339(22):1565-77
references.pmid: 9828244
references.citation: Biol Blood Marrow Transplant. 2007 Mar;13(3):315-28
references.pmid: 17317585
references.citation: Blood. 2009 Feb 19;113(8):1631-8
references.pmid: 19104080
references.citation: Br J Haematol. 2013 May;161(4):566-77
references.pmid: 23452319
references.citation: Biol Blood Marrow Transplant. 2013 Feb;19(2):247-54
references.pmid: 23041601
references.citation: Blood. 1998 Nov 15;92(10):3515-20
references.pmid: 9808542
references.citation: N Engl J Med. 1998 Apr 2;338(14):962-8
references.pmid: 9521984
references.citation: Leukemia. 2013 Feb;27(2):286-94
references.pmid: 22806066
references.citation: Blood. 2007 Oct 1;110(7):2235-41
references.pmid: 17554059
references.citation: Blood. 1995 Aug 15;86(4):1606-13
references.pmid: 7632970
references.citation: Bone Marrow Transplant. 1994;14 Suppl 4:S34-8
references.pmid: 7728122
references.citation: Transplantation. 2005 May 27;79(10):1351-7
references.pmid: 15912103
references.citation: Blood. 2010 Jun 10;115(23):4664-70
references.pmid: 20335219
references.citation: Haematologica. 2013 May;98(5):814-22
references.pmid: 23349300
references.citation: J Clin Oncol. 1997 May;15(5):1767-77
references.pmid: 9164184
references.citation: Blood. 2013 Jan 31;121(5):752-8
references.pmid: 23223509
references.citation: Biol Blood Marrow Transplant. 2011 May;17(5):640-8
references.pmid: 20674756
references.citation: Biol Blood Marrow Transplant. 2008 Jun;14(6):641-50
references.pmid: 18489989
references.citation: Lancet Oncol. 2011 Dec;12(13):1214-21
references.pmid: 21982422
references.citation: Blood. 2011 Oct 6;118(14):3969-78
references.pmid: 21750317
references.citation: J Clin Oncol. 2008 Nov 10;26(32):5183-91
references.pmid: 18768435
references.citation: N Engl J Med. 1989 Jan 26;320(4):197-204
references.pmid: 2643045
references.citation: J Clin Oncol. 2006 Dec 20;24(36):5695-702
references.pmid: 17116940
references.citation: Blood. 2010 Mar 4;115(9):1843-9
references.pmid: 20029048
references.citation: N Engl J Med. 2004 Nov 25;351(22):2276-85
references.pmid: 15564544
references.citation: Blood. 1996 Aug 1;88(3):795-802
references.pmid: 8704232
references.citation: J Clin Oncol. 2005 May 20;23(15):3447-54
references.pmid: 15753458
references.citation: Lancet. 2007 Jun 9;369(9577):1947-54
references.pmid: 17560447